# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ:ALRN), a biopharmaceutical company advancing a ...
Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate o...
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both patholo...
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240124518
Ladenburg Thalmann analyst Aydin Huseynov maintains Aileron Therapeutics (NASDAQ:ALRN) with a Buy and raises the price targe...
Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(1.54) per share versus losses of $(1.00) per share from the s...